======= C9orf41 =======
== Gene Information ==
* **Official Symbol**: CARNMT1
* **Official Name**: carnosine N-methyltransferase 1
* **Aliases and Previous Symbols**: N/A
* **Entrez ID**: [[https://www.ncbi.nlm.nih.gov/gene/?term=138199|138199]]
* **UniProt**: [[https://www.uniprot.org/uniprot/Q8N4J0|Q8N4J0]]
* **Interactions**: [[https://thebiogrid.org/search.php?search=C9orf41&organism=9606|BioGRID]]
* **PubMed articles**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20C9orf41|Open PubMed]]
* **OMIM**: [[https://omim.org/entry/616552|Open OMIM]]
== Function Summary ==
* **Entrez Summary**: N/A
* **UniProt Summary**: N-methyltransferase that mediates the formation of anserine (beta-alanyl-N(Pi)-methyl-L-histidine) from carnosine. Anserine, a methylated derivative of carnosine (beta-alanyl-L- histidine), is an abundant constituent of vertebrate skeletal muscles. Also methylates other L-histidine-containing di- and tripeptides such as Gly-Gly-His, Gly-His and homocarnosine (GABA- His). {ECO:0000269|PubMed:26001783}.
|N2227|
|carnosine N-methyltransferase activity|
|carnosine metabolic process|
|histidine catabolic process|
|imidazole-containing compound catabolic process|
|histidine metabolic process|
|S-adenosylmethionine-dependent methyltransferase activity|
|imidazole-containing compound metabolic process|
|aromatic amino acid family catabolic process|
|aromatic amino acid family metabolic process|
|alpha-amino acid catabolic process|
|cellular amino acid catabolic process|
|cellular modified amino acid metabolic process|
|alpha-amino acid metabolic process|
|carboxylic acid catabolic process|
|organic acid catabolic process|
|cellular amino acid metabolic process|
|methylation|
|heterocycle catabolic process|
|cellular nitrogen compound catabolic process|
|small molecule catabolic process|
|aromatic compound catabolic process|
|organic cyclic compound catabolic process|
|drug metabolic process|
|peptide metabolic process|
|cellular amide metabolic process|
|carboxylic acid metabolic process|
|oxoacid metabolic process|
|organic acid metabolic process|
|organonitrogen compound catabolic process|
|small molecule metabolic process|
|organic substance catabolic process|
|cellular catabolic process|
\\
=== CRISPR Data ===
^Screen^Score^
|[[:results:exp485|GSK626616 14μM R08 exp485]]|-2.51|
|[[:results:exp116|AICAR 240μM R03 exp116]]|-2.2|
|[[:results:exp440|Aphidicolin 0.4μM R08 exp440]]|-1.85|
|[[:results:exp517|Quercetin 20μM R08 exp517]]|-1.85|
|[[:results:exp460|BML-284 0.09μM R08 exp460]]|-1.83|
|[[:results:exp445|∆-9-Tetrahydrocannabinol 30μM R08 exp445]]|-1.83|
|[[:results:exp374|Latrunculin-B 10μM R07 exp374]]|-1.7|
|[[:results:exp146|Quinacrine 2.5μM R03 exp146]]|1.73|
|[[:results:exp30|Rapamycin 10μM R00 exp30]]|1.87|
|[[:results:exp226|Cerivastatin 0.15μM R05 exp226]]|1.94|
|[[:results:exp198|Etoposide 0.1μM R05 exp198]]|2.11|
|[[:results:exp301|VER-155008 3.9μM R06 exp301]]|2.2|
|[[:results:exp21|MLN-4924 0.2μM R00 exp21]]|2.26|
|[[:results:exp501|Methotrexate 0.01μM R08 exp501]]|2.29|
|[[:results:exp282|Fluvastatin 2.2μM R06 exp282]]|2.71|
|[[:results:exp335|Aminopterin 0.005μM R07 exp335]]|3.64|
|[[:results:exp264|Arsenate 40μM R06 exp264]]|3.9|
No correlation found to any other genes in chemogenomics.
Global Fraction of Cell Lines Where Essential: 0/739
^Tissue^Fraction Of Cell Lines Where Essential^
|1290807.0|0/1|
|909776.0|0/1|
|bile duct|0/28|
|blood|0/28|
|bone|0/26|
|breast|0/33|
|central nervous system|0/56|
|cervix|0/4|
|colorectal|0/17|
|esophagus|0/13|
|fibroblast|0/1|
|gastric|0/16|
|kidney|0/21|
|liver|0/20|
|lung|0/75|
|lymphocyte|0/16|
|ovary|0/26|
|pancreas|0/24|
|peripheral nervous system|0/16|
|plasma cell|0/15|
|prostate|0/1|
|skin|0/24|
|soft tissue|0/9|
|thyroid|0/2|
|upper aerodigestive|0/22|
|urinary tract|0/29|
|uterus|0/5|
== Essentiality in NALM6 ==
* **Essentiality Rank**: 2169
* **Expression level (log2 read counts)**: 5.46
{{:chemogenomics:nalm6 dist.png?nolink |}}